St Andrews Research Repository

St Andrews University Home
View Item 
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  •   St Andrews Research Repository
  • University of St Andrews Research
  • University of St Andrews Research
  • University of St Andrews Research
  • View Item
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.

A dose ranging trial to optimize the dose of Rifampin in the treatment of tuberculosis

Thumbnail
View/Open
final_submission_minor_revision_18122014.pdf (1.290Mb)
Date
01/05/2015
Author
Boeree, Martin J
Diacon, Andreas H
Dawson, Rodney
Narunsky, Kim
du Bois, Jeannine
Venter, Amour
Phillips, Patrick P J
Gillespie, Stephen H
Mc Hugh, Timothy D
Hoelscher, Michael
Heinrich, Norbert
Rehal, Sunita
van Soolingen, Dick
van Ingen, Jakko
Magis-Escurra, Cecile
Burger, David
Plemper van Balen, Georgette
Aarnoutse, Rob E
PanACEA Consortium
Keywords
Tuberculosis
Clinical trial
Rifampicin
Global health
RM Therapeutics. Pharmacology
NDAS
BDC
R2C
~DC~
SDG 3 - Good Health and Well-being
Metadata
Show full item record
Altmetrics Handle Statistics
Altmetrics DOI Statistics
Abstract
Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on pharmacokinetic, toxicity and cost considerations. Available data in mice and humans showed that an increase in dose may shorten the duration of tuberculosis treatment. Objectives: To evaluate the safety and tolerability, the pharmacokinetics and the extended early bactericidal activity of increasing doses of rifampin. Methods: Patients with drug-susceptible tuberculosis were enrolled into a control group of 8 patients receiving the standard dose of 10 mg/kg rifampin, followed by consecutive experimental groups with 15 patients each receiving rifampin 20 mg/kg, 25 mg/kg, 30 mg/kg and 35 mg/kg, respectively, for 14 days. In all patients isoniazid, pyrazinamide and ethambutol were added in standard doses for the second 7 days of treatment. Safety, pharmacokinetics of rifampin, and fall in bacterial load were assessed. Measurements and Main Results: Grade 1 and 2 adverse events were equally distributed between the five dose groups; there were 5 grade 3 events of which 1 was a possibly related hepatotoxicity. Areas under the time-concentration curves and peak serum concentrations of rifampin showed a more than proportional increase with dose. The daily fall in bacterial load over 14 days was 0.176, 0.168, 0.167, 0.265, and 0.261 log10CFU/ml sputum in the 10, 20, 25, 30 and 35 mg/kg groups respectively. Conclusions: Two weeks of rifampin up to 35 mg/kg was safe and well tolerated. There was a non-linear increase in exposure to rifampin without an apparent ceiling effect and a greater estimated fall in bacterial load in the higher dosing groups. Clinical trial registration available at www.clinicaltrials.gove, ID NCT01392911.
Citation
Boeree , M J , Diacon , A H , Dawson , R , Narunsky , K , du Bois , J , Venter , A , Phillips , P P J , Gillespie , S H , Mc Hugh , T D , Hoelscher , M , Heinrich , N , Rehal , S , van Soolingen , D , van Ingen , J , Magis-Escurra , C , Burger , D , Plemper van Balen , G , Aarnoutse , R E & PanACEA Consortium 2015 , ' A dose ranging trial to optimize the dose of Rifampin in the treatment of tuberculosis ' , American Journal of Respiratory and Critical Care Medicine , vol. 191 , no. 9 , pp. 1058-1065 . https://doi.org/10.1164/rccm.201407-1264OC
Publication
American Journal of Respiratory and Critical Care Medicine
Status
Peer reviewed
DOI
https://doi.org/10.1164/rccm.201407-1264OC
ISSN
1073-449X
Type
Journal article
Rights
© 2015, Publisher / the Author(s). This work is made available online in accordance with the publisher’s policies. This is the author created, accepted version manuscript following peer review and may differ slightly from the final published version. The final published version of this work is available at www.atsjournals.org / https://dx.doi.org/10.1164/rccm.201407-1264OC
Description
The study was funded by the EDCTP (European & Developing Countries Clinical Trials Partnership), NACCAP (Netherlands-African partnership for Capacity development and Clinical interventions Against Poverty-related diseases) and the Bill & Melinda Gates Foundation.
Collections
  • University of St Andrews Research
URI
http://hdl.handle.net/10023/8455

Items in the St Andrews Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

Advanced Search

Browse

All of RepositoryCommunities & CollectionsBy Issue DateNamesTitlesSubjectsClassificationTypeFunderThis CollectionBy Issue DateNamesTitlesSubjectsClassificationTypeFunder

My Account

Login

Open Access

To find out how you can benefit from open access to research, see our library web pages and Open Access blog. For open access help contact: openaccess@st-andrews.ac.uk.

Accessibility

Read our Accessibility statement.

How to submit research papers

The full text of research papers can be submitted to the repository via Pure, the University's research information system. For help see our guide: How to deposit in Pure.

Electronic thesis deposit

Help with deposit.

Repository help

For repository help contact: Digital-Repository@st-andrews.ac.uk.

Give Feedback

Cookie policy

This site may use cookies. Please see Terms and Conditions.

Usage statistics

COUNTER-compliant statistics on downloads from the repository are available from the IRUS-UK Service. Contact us for information.

© University of St Andrews Library

University of St Andrews is a charity registered in Scotland, No SC013532.

  • Facebook
  • Twitter